Five-Year Outcomes From a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer


      Single-institution studies suggest stereotactic body radiotherapy (SBRT) is a cost-effective alternative to IMRT as primary therapy for prostate cancer. We hypothesized that dose-escalated SBRT could be safely administered across multiple institutions, with grade 3+ toxicities not exceeding 10%. With median follow up greater than five years, we report toxicity, survival, and relapse-free survival (RFS) outcomes.


      After completing rigorous credentialing requirements, 21 community, regional, and academic hospitals enrolled 309 evaluable patients with biopsy-proven adenocarcinoma of the prostate, confirmed by central pathologic review: 172 low-risk (CS T1-T2a, Gleason 6, PSA < 10 ng/mL) and 137 intermediate-risk (CS T1c-T2b with either Gleason = 7 and PSA < 10 ng/mL, or Gleason 6 and PSA between 10 and 20 ng/mL). All patients were treated with a non-isocentric robotic SBRT platform using real-time tracking of implanted fiducials. The prostate was prescribed 40 Gy in 5 fractions of 8 Gy and seminal vesicles received 36.25 Gy. Normal tissues were rigidly constrained (rectal V36 Gy <1 cc; bladder V37 Gy <5-10 cc). No patient had concomitant or adjuvant androgen ablation therapy. Toxicities were assessed using CTCAE v3 criteria. Patient-reported quality of life outcomes were recorded and reported elsewhere. Biochemical failure was assessed using the ASTRO consensus and the nadir + 2 definitions. Actuarial survival outcomes were calculated using Kaplan Meier methods. The study populations yielded a 90% power of identifying excessive (>10%) rates of grade 3+ GU or GI toxicities at the one-sided 5% significance level.


      Median follow-up was 61 months. Five grade 3+ toxicities (1.6%) were reported, far below the 10% rate deemed excessive. There were no grade 4 or 5 toxicities. All reported grade 3 toxicities were GU; these occurred between 11 and 51 months after treatment. Toxicities rates are summarized below. Five patients (1.6%) developed urinary retention which required a temporary catheter placement. Seven patients were diagnosed with bladder cancers between 21 and 50 months after treatment. For the entire population, actuarial 5-year overall survival was 95.6%. Actuarial 5-year nadir +2 RFS was 97.1% for all patients, and was 97.3% and 97.1% for the low- and intermediate-risk groups, respectively. Actuarial 5-year ASTRO RFS was 92.3% and 91.3% for these respective risk groups.


      With appropriate treatment delivery and constraints, dose-escalated prostate SBRT can be safely administered across multiple institutions. Toxicity rates and RFS rates compare favorably to other radiotherapies. SBRT appears to be a suitable option for low- and intermediate-risk prostate cancer. identifier NCT00643994.
      Tabled 1Abstract 74; Table 1
      GU ToxicityGI Toxicity
      Any time165 (53%)108 (35%)5 (2%)0183 (59%)31 (10%)0
      < 3 mos182 (59%)79 (26%)00169 (55%)25 (8%)0
      > 3 mos87 (28%)38 (12%)5 (2%)038 (12%)6 (2%)0


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.